Section	Item	PRISMA-ScR Checklist Item	Reported on Page #
Title
Title	1	Identify the report as a scoping review.	This has been stated in the introduction and methodology sections
Abstract
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results and conclusions that relate to the review questions and objectives.	All these points are reported in the abstract.
Introduction
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	This is stated in the introduction section whereby the reason for this review is to surface key elements of care coordination as more patients with chronic diseases need to be firmly anchored in the community.
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	This is mentioned in the introduction which aims to uncover the broad themes surrounding chronic disease management programmes with significant care coordination components while illuminating the under-researched areas requiring further exploration.
Methods
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	The entire review protocol is elaborated in the methodology section.
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language and publication status), and provide a rationale.	This is fully mentioned in the methodology section.
Information sources	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	This is fully mentioned in the methodology section.
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	This is fully mentioned in the methodology section and Appendix D.
Selection of sources of evidence	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	This is mentioned in Appendix B and Appendix D.
Data charting process	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	This is fully mentioned in the methodology section and the PRISMA diagram shows how the team managed repeated and non-relevant articles.
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	This is highlighted in both the introduction and methodology sections which also includes our operational definition of care coordination.
Critical appraisal of individual sources of evidence	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	NA
Synthesis of results	13	Describe the methods of handling and summarising the data that were charted.	This is mentioned in the methodology section in terms of how data is extracted and thematically analysed by the study team. A PESTLE framework was used to guide the initial analysis.
Results
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	The inclusion and exclusion criteria are reported in Appendix B and in Figure 1.
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	The summary of programmatic characteristics is stated in the results section with the associated references.
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	NA
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	The summary of programmatic characteristics is stated in the results section with the associated references and in Table 1.
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	The summary of programmatic characteristics is stated in the results section with the associated references and Table 1.
Discussion
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	The summary of programmatic characteristics is stated in the results section with the associated references and Table 1.
Limitations	20	Discuss the limitations of the scoping review process.	This is discussed in the limitation section of the manuscript.
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	This is elaborated in the discussion and “Aligning with Singapore’s national healthcare strategies and recommendations” section.
Funding
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	This is mentioned under the funding section.